Abstract
AbstractIndazole‐based vitronectin receptor antagonists have been conjugated to chelators DOTA and Hynic using a variety of tethers and pharmacokinetic modifying groups. All modifications resulted in potent αvβ3 antagonists in an Elisa assay. The chelator conjugates were radiolabeled with 111In (DOTA) and 99mTc (Hynic) in >90% RCP. Biodistribution studies in the c‐Neu Oncomouse tumor model have shown high tumor uptake and primarily renal excretion for these agents. The potential use of these agents in cancer diagnosis will be discussed.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call